肝细胞癌风险分层模型的开发与验证:转化肝癌联盟框架
美国国家癌症研究所转化肝癌联盟召集多学科专家组,提出肝细胞癌风险分层模型开发与验证的四阶段框架:开发与内部验证、决策规则制定、外部验证和影响评估,并给出提高严谨性的推荐意见,以推动模型进入临床实践和指南认可。
要点
- 框架定义风险分层模型开发与验证的四阶段:开发与内部验证、决策规则、外部验证、影响评估。
- 指南推荐对任何病因肝硬化及有额外危险因素的慢性乙肝患者进行肝癌监测,但各组发病率不同。
- 多数风险分层模型在乙肝患者中应用,在肝硬化患者中充分验证的模型较少。
核心结论
- 提出肝细胞癌风险分层模型开发与验证的四阶段框架及提高严谨性的推荐意见,为模型进入临床实践和指南认可提供路径。
研究设计与样本
- 美国国家癌症研究所转化肝癌联盟召集美国、亚洲和欧洲的临床医生、科学家、生物统计学家和技术专家组成多学科专家组制定框架。
主要发现
- 风险分层模型开发与验证分为四阶段:阶段1开发与内部验证,阶段2决策规则制定,阶段3外部验证,阶段4影响评估。
- 专家组定义了一套推荐意见以提高肝细胞癌风险分层策略开发与验证的严谨性。
- 尽管风险分层模型用于乙肝患者,但在肝硬化患者中充分验证的模型较少。
关键数值与推荐
- 临床实践指南推荐对任何病因肝硬化患者以及有额外危险因素的慢性乙肝病毒感染患者进行肝细胞癌监测。
- 风险分层模型开发与验证框架包含四个阶段:开发与内部验证、决策规则制定、外部验证、影响评估。
临床怎么用
- 该框架可指导肝细胞癌风险分层模型开发与验证的最佳实践,并明确实践指南和监管机构认可所需的步骤。
- 在广泛推荐实施风险分层模型前,需解决模型开发、验证和影响评估相关的未答问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical practice guidelines recommend hepatocellular cancer (HCC) surveillance in patients with cirrhosis from any etiology and those with chronic hepatitis B virus (HBV) infection and additional risk factors. However, HCC incidence varies across groups. Several risk stratification models using clinical factors and/or biomarkers have been derived to facilitate tailored HCC surveillance. Although risk stratification models are used for patients with hepatitis B, few have been sufficiently validated in patients with cirrhosis. Indeed, many unanswered questions related to the development, validation, and impact evaluation of risk stratification models must be addressed before widespread implementation can be recommended. The National Cancer Institute's Translational Liver Cancer (TLC) Consortium was established to advance research focused on risk stratification and early detection of liver cancer. The TLC convened a multidisciplinary group, including clinicians, scientists, biostatisticians, and technology experts from the United States, Asia, and Europe, to provide a framework for the development, validation, and implementation of risk stratification models. The framework defines 4 phases of risk stratification model development and validation: phase 1 -development and internal validation, phase 2 -decision rule development, phase 3 -external validation, and phase 4 -impact evaluation. The group also defined a set of recommendations to improve the rigor of development and validation of HCC risk stratification strategies. This framework can inform best practices and highlight necessary steps for endorsement by practice guidelines and regulatory agencies, highlighting a path toward implementation in clinical practice.
引用
- Kanwal F, Feng Z, Hoshida Y, et al. Development and validation of risk stratification models for hepatocellular cancer: A framework from the translational liver cancer consortium. Hepatology. 2026. PMID: 42008824. doi:10.1097/HEP.0000000000001745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。